Skip Navigation


JAC Advance Access originally published online on February 10, 2005
Journal of Antimicrobial Chemotherapy 2005 55(3):396-398; doi:10.1093/jac/dki019
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/3/396    most recent
dki019v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Decousser, J.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decousser, J.-W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.3 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Correspondence

In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains

Jean-Winoc Decousser1,2,*, Imen Methlouthi1, Patrick Pina3 and Pierre Allouch1 on behalf of The ColBVH Study{dagger}

1 Service d'Hygiène Hospitalière, Centre Hospitalier de Versailles André Mignot, 177 rue de Versailles, 78150 Le Chesnay; 2 Equipe Opérationnelle d'Hygiène, Laboratoire de Biologie, Centre Hospitalier de Dourdan, 2 rue du Potelet, 91415 Dourdan; 3 Service de Médecine B, Hôpital de Plaisir Grignon, 220 rue Mansart, 78375 Plaisir, France

*Corresponding author. Tel: +33-1-6081-5892; Fax: +33-1-6081-5897; Email: Jean-Winoc.Decousser@wanadoo.fr

Keywords: carbapenems , Streptococcus pneumoniae , France , bacteraemia

The first 10% of the full text of this article appears below.

Sir,

Streptococcus pneumoniae is the most common cause of infections of the lower respiratory tract in adults and children. In Europe, France has the highest rates of penicillin and erythromycin resistance in pneumococci: in 2002, 53% and 58% of the strains were found to be non-susceptible to these antibiotics, respectively.1 In American guidelines (but not in French guidelines), ertapenem, a newly licensed parenteral carbapenem, constitutes an alternative to the usual parenteral ß-lactams for inpatients with pneumococcal infection.2 The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?